TMCI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

61.76M

-10.11%

-0.150

+1399.4%

52.02M

-1.05%

-0.242

-3.33%

47.40M

+0.02%

-0.255

-8.79%

Estimates Revision

The market is revising Downward the revenue expectations for Treace Medical Concepts, Inc. (TMCI) for FY2025, with the revenue forecasts being adjusted by -5.44% over the past three months. During the same period, the stock price has changed by -50.68%.

Revenue Estimates for FY2025

Revise Downward

-5.44%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+13.45%

In Past 3 Month

Stock Price

Go Down

-50.68%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast TMCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMCI is 5.47 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

1 Sell

Hold

Current: 0.000

Low

4.00

Averages

5.47

High

7.50

Current: 0.000

Low

4.00

Averages

5.47

High

7.50

Truist

Richard Newitter

Hold

downgrade

$4 -> $3

2025-12-18

Reason

Truist

Richard Newitter

Price Target

$4 -> $3

2025-12-18

downgrade

Hold

Reason

Truist analyst Richard Newitter lowered the firm's price target on Treace Medical to $3 from $4 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Truist

Richard Newitter

Hold

downgrade

$7 -> $4

2025-11-10

Reason

Truist

Richard Newitter

Price Target

$7 -> $4

2025-11-10

downgrade

Hold

Reason

Truist analyst Richard Newitter lowered the firm's price target on Treace Medical to $4 from $7 and keeps a Hold rating on the shares after its Q3 results and updated outlook. The guide-down implies a return to negative revenue growth in Q4 as contribution from new osteotomy product launches are masked by incremental share loss in core lapiplasty, the analyst tells investors in a research note.

UBS

Neutral

downgrade

2025-11-07

Reason

UBS

Price Target

2025-11-07

downgrade

Neutral

Reason

UBS lowered the firm's price target on Treace Medical to $5.85 from $6.50 and keeps a Neutral rating on the shares.

Lake Street

Ben Haynor

Buy

downgrade

$12

2025-11-07

Reason

Lake Street

Ben Haynor

Price Target

$12

2025-11-07

downgrade

Buy

Reason

Lake Street analyst Ben Haynor lowered the firm's price target on Treace Medical to $7.50 from $12 and keeps a Buy rating on the shares. A roughly 10% sales decline is now implied for Q4 where the firm and consensus had previously modeled growth of about 13%, notes the analyst, who adds that there is "no question updated guidance for FY2025 represented a massive disappointment."

Stifel

Hold

downgrade

$6 -> $5

2025-11-07

Reason

Stifel

Price Target

$6 -> $5

2025-11-07

downgrade

Hold

Reason

Stifel lowered the firm's price target on Treace Medical to $5 from $6 and keeps a Hold rating on the shares. The company's Q3 and 2025 guidance update were more complicated than anticipated, as sales did outperform, but management indicated on the call that ta distributor order of roughly $6M made Q3 appear better than the underlying business reality, the analyst tells investors in a research note. The firm noted, however, that CEO John Treace did highlight several factors that support the potential for both more consistent execution and an improved outlook ahead.

JPMorgan

Lilia-Celine Lozada

Neutral -> Underweight

downgrade

$8 -> $5

2025-11-07

Reason

JPMorgan

Lilia-Celine Lozada

Price Target

$8 -> $5

2025-11-07

downgrade

Neutral -> Underweight

Reason

JPMorgan analyst Lilia-Celine Lozada downgraded Treace Medical to Underweight from Neutral with a price target of $5, down from $8. The company's earnings update is "disappointing" as the better than expected quarter was overshadowed by a reset to guidance as softness in the foot and ankle market, a shift away from Lapiplasty, and a mix headwind from new launches are set to pressure revenues in the near-term, the analyst tells investors in a research note. The firm sees multiple headwinds pressuring Treace Medical's near-term growth "and no clear timing of resolution."

Valuation Metrics

The current forward P/E ratio for Treace Medical Concepts Inc (TMCI.O) is -2.83, compared to its 5-year average forward P/E of -31.14. For a more detailed relative valuation and DCF analysis to assess Treace Medical Concepts Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-31.14

Current PE

-2.83

Overvalued PE

2.61

Undervalued PE

-64.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

33.81

Current EV/EBITDA

-34.80

Overvalued EV/EBITDA

525.19

Undervalued EV/EBITDA

-457.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.68

Current PS

0.75

Overvalued PS

9.73

Undervalued PS

1.64

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TMCI News & Events

Events Timeline

No data

News

3.5

01-08Globenewswire

Treace Completes First Surgery Using Lapiplasty®Lightning™ Technology

1.0

2025-12-30Globenewswire

Treace Medical CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026

9.0

2025-12-17NASDAQ.COM

Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise

People Also Watch

Frequently Asked Questions

What is Treace Medical Concepts Inc (TMCI) stock price today?

The current price of TMCI is 2.9 USD — it has decreased -2.03 % in the last trading day.

What is Treace Medical Concepts Inc (TMCI)'s business?

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.

What is the price predicton of TMCI Stock?

What is Treace Medical Concepts Inc (TMCI)'s revenue for the last quarter?

Treace Medical Concepts Inc revenue for the last quarter amounts to 50.21M USD, increased 11.37 % YoY.

What is Treace Medical Concepts Inc (TMCI)'s earnings per share (EPS) for the last quarter?

Treace Medical Concepts Inc. EPS for the last quarter amounts to -0.26 USD, increased 4.00 % YoY.

What changes have occurred in the market's expectations for Treace Medical Concepts Inc (TMCI)'s fundamentals?

How many employees does Treace Medical Concepts Inc (TMCI). have?

Treace Medical Concepts Inc (TMCI) has 477 emplpoyees as of January 10 2026.

What is Treace Medical Concepts Inc (TMCI) market cap?

Today TMCI has the market capitalization of 184.78M USD.